Literature DB >> 18640764

Mucin1 expression is enriched in the human stem cell fraction of cord blood and is upregulated in majority of the AML cases.

Szabolcs Fatrai1, Hein Schepers, Henko Tadema, Edo Vellenga, Simon M G J Daenen, Jan Jacob Schuringa.   

Abstract

OBJECTIVE: Mucin1 is a membrane glycoprotein that is overexpressed in a variety of human cancers. Here, we analyzed the role of Mucin1 in human hematopoietic stem/progenitor cells as well as in acute myeloid leukemia (AML) cells.
MATERIALS AND METHODS: Mucin1 expression was determined within the normal stem cell and progenitor compartment, as well as in the AML CD34+ and CD34- subfractions of patient samples. Stem cells were enumerated in long-term culture-initiating cell (LTC-IC) assays in limiting dilution and progenitor frequencies in colony-forming cell (CFC) assays in methylcellulose, and consequences of elevated Mucin1 expression were studied using retroviral overexpression systems in cord blood (CB) CD34+ cells.
RESULTS: Ten percent of CB and 5% of peripheral blood CD34+ cells expressed Mucin1. Retroviral overexpression of Mucin1 in CB CD34+ cells resulted in elevated stem cell and progenitor frequencies as determined in LTC-IC and CFC assays without affecting differentiation, which coincided with increased proliferation. Overexpression of intercellular adhesion molecule-1, a ligand for Mucin1, in MS5 stromal cells further increased LTC-IC frequencies. Mucin1 overexpression was associated with increased nuclear factor-kappaB p50 nuclear translocation, suggesting that Mucin1-induced phenotypes involve increased cell survival mechanisms. Finally, we observed increased Mucin1 expression in 70% of the AML cases (n=24), suggesting that elevated Mucin1 levels might be involved in regulating the proliferative potential of the immature leukemic compartment as well.
CONCLUSIONS: Our data indicate that hematopoietic stem cells as well as CD34+ AML subfractions are enriched for Mucin1 expression, and that overexpression of Mucin1 in CB cells is sufficient to increase both progenitor and LTC-IC frequencies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18640764     DOI: 10.1016/j.exphem.2008.04.015

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  19 in total

1.  MUC1-C oncoprotein suppresses reactive oxygen species-induced terminal differentiation of acute myelogenous leukemia cells.

Authors:  Li Yin; Zekui Wu; David Avigan; Jacalyn Rosenblatt; Richard Stone; Surender Kharbanda; Donald Kufe
Journal:  Blood       Date:  2011-03-21       Impact factor: 22.113

2.  Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma.

Authors:  Salvia Jain; Dina Stroopinsky; Li Yin; Jacalyn Rosenblatt; Maroof Alam; Parul Bhargava; Rachael A Clark; Thomas S Kupper; Kristen Palmer; Maxwell D Coll; Hasan Rajabi; Athalia Pyzer; Michal Bar-Natan; Katarina Luptakova; Jon Arnason; Robin Joyce; Donald Kufe; David Avigan
Journal:  Blood       Date:  2015-06-05       Impact factor: 22.113

3.  MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells.

Authors:  Suiyang Liu; Li Yin; Dina Stroopinsky; Hasan Rajabi; Alexandre Puissant; Kimberly Stegmaier; David Avigan; Surender Kharbanda; Donald Kufe; Richard Stone
Journal:  Blood       Date:  2013-11-26       Impact factor: 22.113

Review 4.  Mucins in cancer: function, prognosis and therapy.

Authors:  Donald W Kufe
Journal:  Nat Rev Cancer       Date:  2009-12       Impact factor: 60.716

5.  Lack of Muc1-regulated beta-catenin stability results in aberrant expansion of CD11b+Gr1+ myeloid-derived suppressor cells from the bone marrow.

Authors:  Tze Wei Poh; Judy M Bradley; Pinku Mukherjee; Sandra J Gendler
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

Review 6.  MUC1 in hematological malignancies.

Authors:  Dina Stroopinsky; Donald Kufe; David Avigan
Journal:  Leuk Lymphoma       Date:  2016-06-27

7.  MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells.

Authors:  Dina Stroopinsky; Jacalyn Rosenblatt; Keisuke Ito; Heidi Mills; Li Yin; Hasan Rajabi; Baldev Vasir; Turner Kufe; Katarina Luptakova; Jon Arnason; Caterina Nardella; James D Levine; Robin M Joyce; Ilene Galinsky; Yoram Reiter; Richard M Stone; Pier Paolo Pandolfi; Donald Kufe; David Avigan
Journal:  Cancer Res       Date:  2013-07-18       Impact factor: 12.701

8.  Downregulation of hematopoietic MUC1 during experimental colitis increases tumor-promoting myeloid-derived suppressor cells.

Authors:  Tze Wei Poh; Cathy S Madsen; Jessica E Gorman; Ronald J Marler; Jonathan A Leighton; Peter A Cohen; Sandra J Gendler
Journal:  Clin Cancer Res       Date:  2013-07-19       Impact factor: 12.531

9.  Maximal STAT5-induced proliferation and self-renewal at intermediate STAT5 activity levels.

Authors:  Albertus T J Wierenga; Edo Vellenga; Jan Jacob Schuringa
Journal:  Mol Cell Biol       Date:  2008-09-08       Impact factor: 4.272

10.  Single-cell STAT5 signal transduction profiling in normal and leukemic stem and progenitor cell populations reveals highly distinct cytokine responses.

Authors:  Lina Han; Albertus T J Wierenga; Marjan Rozenveld-Geugien; Kim van de Lande; Edo Vellenga; Jan Jacob Schuringa
Journal:  PLoS One       Date:  2009-11-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.